Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q4 FY23 results · Jan–Mar 2023
Aarti Drugs reported revenue from operations of ₹742.41 crore (up 6.9% from Q4 FY22) and net profit of ₹56.18 crore (up 1.6% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 742.41 | 694.27 | +6.9% | 663.96 | +11.8% |
| Other income | 0.87 | 2.96 | −70.6% | 1.01 | −13.9% |
| Total income | 743.28 | 697.23 | +6.6% | 664.97 | +11.8% |
| Profit before tax | 73.28 | 70.50 | +3.9% | 49.68 | +47.5% |
| Net profit for the period | 56.18 | 55.32 | +1.6% | 36.67 | +53.2% |
| Attributable to shareholders of the company | 56.09 | 55.34 | +1.4% | 36.68 | +52.9% |
| EPS, basic (₹) | 6.07 | 5.97 | +1.7% | 3.96 | +53.3% |
| Net margin (%) | 7.6 | 8.0 | 5.5 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 696.41 | 641.48 | +8.6% | 625.53 | +11.3% |
| Other income | 0.93 | 0.62 | +50.0% | 0.97 | −4.1% |
| Total income | 697.34 | 642.10 | +8.6% | 626.50 | +11.3% |
| Profit before tax | 69.42 | 67.00 | +3.6% | 48.96 | +41.8% |
| Net profit for the period | 53.17 | 53.00 | +0.3% | 36.71 | +44.8% |
| EPS, basic (₹) | 5.74 | 5.72 | +0.3% | 3.96 | +44.9% |
| Net margin (%) | 7.6 | 8.3 | 5.9 |
Consolidated
- Filed with BSE
- 02 May 2023, 15:43 IST
- Board meeting
- 29 Apr 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 May 2023, 15:43 IST
- Board meeting
- 29 Apr 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE